Search

Risk-reducing salpingo-oophorectomy brings on early menopause and its attendant consequences. Researchers are exploring whether a less drastic surgical strategy can offer a safe and efficacious option.

… Friday, September 16, 2016 Since there is no effective screening test for ovarian cancer , the gold standard management approach for women who are at an increased risk for developing ovarian cancer is a risk-reducing salpingo-oophorectomy (RRSO), a surgical procedure to remove ovaries and fallopian tubes

Many women are confused by conflicting guidelines on breast screening. And the latest recommendations made by the USPSTF are adding to that confusion. MSK experts are available to answer questions and explain what MSK recommends and why it is not altering its guidelines. To schedule an interview with a member of MSK’s breast cancer leadership team, please contact Nicole McNamara at [email protected].

… Monday, January 11, 2016 Many women are confused by conflicting guidelines on breast screening. And the latest recommendations made by the USPSTF are adding to that confusion. MSK experts are available to answer questions and explain what MSK recommends and why it is not altering its guidelines. To schedule

Women and ethnic minorities are underrepresented in science. Memorial Sloan Kettering is working to change that.

… Friday, November 2, 2018 Edwin Kamau (NYU) and Laura González-Fajardo (University of Connecticut) Graduate students Edwin Kamau (NYU) and Laura González-Fajardo (University of Connecticut) Patrick Cherubin (University of Central Florida) and Michael Riley II (University of Florida) Graduate students

Overcoming resistance to drug treatment for lung cancer is a critical challenge.

… Thursday, November 29, 2018 Summary Investigators are looking for ways to overcome resistance to drugs that target lung cancer. Lung cancer was one of the first cancers that could be targeted by drugs aimed at specific mutations in tumors. Advances in genomic medicine and the molecular analysis of tumors

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.

… Wednesday, September 27, 2006 Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate

Learn how CAR T cell therapy and the expertise of MSK gave Guillaume Arnould another option for treating multiple myeloma, after other therapies failed.

… Tuesday, November 7, 2023 Shortly after finding out his wife was pregnant with their son, Guillaume Arnould got terrible news about his own health: He had multiple myeloma , a rare blood cancer. He was just 33 years old. The following six years were a grueling succession of stem cell transplants stem

Meet Matthew Solowsky, a Navy veteran and Senior Research Technician in the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center.

… Thursday, November 11, 2021 Matthew Solowsky says he has always been driven and focused. “The hardships from my childhood made me want to rise above circumstances that were outside of myself,” says Mr. Solowsky, who is now a Senior Research Technician in the Center for Molecular Oncology (CMO)  at Memorial

Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma and glofitamab (glofit) for patients with relapsed or refractory diffuse B cell lymphoma (DLBCL) or large B cell lymphoma (LBCL) treated with two or more prior lines of therapy.

… Monday, December 11, 2023 Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma

Meet author Amy Blumenfeld, whose experience as a pediatric patient at Memorial Sloan Kettering inspired her first novel, The Cast.

… Friday, November 16, 2018 Summary In 1989, 15-year-old Amy Blumenfeld was treated for Hodgkin lymphoma at Memorial Sloan Kettering. Her first novel, The Cast, is loosely based on her experience. In the late 1980s, when she was 13, Amy Blumenfeld was diagnosed with Hodgkin lymphoma. She had 11 months

New MSK research provides insights into how BRCA2 promotes genomic integrity; illuminates how embryonic cells can develop without key amino acids; explores how the microbiome bounces back after antibiotic treatment; and investigates acquired resistance to immunotherapy in non-small cell lung cancer.

… Monday, January 29, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) provides insights into how BRCA2 promotes genomic integrity; illuminates how embryonic cells can develop without key amino acids; explores how the microbiome bounces back after antibiotic treatment; and investigates